Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2002-11, Vol.61 (suppl 2), p.ii2-ii7 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | ii7 |
|---|---|
| container_issue | suppl 2 |
| container_start_page | ii2 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 61 |
| creator | Furst, D E Breedveld, F C Kalden, J R Smolen, J S Antoni, C E Bijlsma, J W J Burmester, G R Cronstein, B Keystone, E C Kavanaugh, A Klareskog, L |
| description | |
| doi_str_mv | 10.1136/ard.61.suppl_2.ii2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1766714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008347651</sourcerecordid><originalsourceid>FETCH-LOGICAL-b532t-99bde8ba8748e2631c3b08f8927c2c419bbd76388a77bd09aac7cd20d52e661a3</originalsourceid><addsrcrecordid>eNqNkUGP0zAQhSMEYsvCH-CALCEQHFJsJ7WdCxJULCAWOMAibtbEdlqXJA4eB7FXfjlGLVvgxMnyzDdPb-YVxV1Gl4xV4glEuxRsifM09ZovvefXigWrhSo5FfR6saCUVmXdCHlS3ELc5S9VTN0sThivZCMYXxQ_LiYLyVliwohuxBkJplwY3JhIGEnrQx823kBPYJNrSLoQSdo6kqKDtMc6ErduHiAFbwnEtI0-eSQwWhIyGn-3vSHWowN0SB69hUvCKeWPbxc3OujR3Tm8p8XF2YuP61fl-fuXr9fPzst2VfFUNk1rnWpByVo5LipmqpaqTjVcGm5q1rStlaJSCqRsLW0AjDSWU7viTggG1WnxdK87ze3grMnWI_R6in6AeKkDeP13Z_RbvQnfNJNCSFZngYcHgRi-zg6THjwa1_cwujCjlpzJulnJDN7_B9yFOY55uawlpaprUdNM8T1lYkCMrruywqj-FbDOAWvB9CFgnQPOQ_f-XOI4ckg0Aw8OAGBOrYswGo9Hrq7y6RqVuXLPeUzu-1Uf4hctZCVX-t2ntf785kyunn-gWhz5dtj9j9Gf0bfS-w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777844640</pqid></control><display><type>article</type><title>Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Furst, D E ; Breedveld, F C ; Kalden, J R ; Smolen, J S ; Antoni, C E ; Bijlsma, J W J ; Burmester, G R ; Cronstein, B ; Keystone, E C ; Kavanaugh, A ; Klareskog, L</creator><creatorcontrib>Furst, D E ; Breedveld, F C ; Kalden, J R ; Smolen, J S ; Antoni, C E ; Bijlsma, J W J ; Burmester, G R ; Cronstein, B ; Keystone, E C ; Kavanaugh, A ; Klareskog, L</creatorcontrib><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.61.suppl_2.ii2</identifier><identifier>PMID: 12379612</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>aCL ; ACR ; American College of Rheumatology ; ANA ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; anticardiolipin antibody ; antinuclear antibody ; Antirheumatic Agents - adverse effects ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - therapy ; biological agents ; Biological and medical sciences ; blocking agents ; Bones, joints and connective tissue. Antiinflammatory agents ; Consensus Statement ; DAS ; disease activity score ; disease modifying antirheumatic drug ; DMARD ; Drug dosages ; HAQ-DI ; Health Assessment Questionnaire disease index ; Humans ; interleukin ; Interleukin-2 - antagonists & inhibitors ; Medical sciences ; methotrexate ; MTX ; Patients ; Pharmacology. Drug treatments ; Rheumatic diseases ; Rheumatic Diseases - therapy ; Rheumatoid arthritis ; TNF ; TNF inhibitors ; Toxicity ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor necrosis factor-TNF ; tumour necrosis factor ; tumour necrosis factor α ; VAS ; visual analogue scale</subject><ispartof>Annals of the rheumatic diseases, 2002-11, Vol.61 (suppl 2), p.ii2-ii7</ispartof><rights>Copyright 2002 by Annals of the Rheumatic Diseases</rights><rights>2003 INIST-CNRS</rights><rights>Copyright: 2002 Copyright 2002 by Annals of the Rheumatic Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b532t-99bde8ba8748e2631c3b08f8927c2c419bbd76388a77bd09aac7cd20d52e661a3</citedby><cites>FETCH-LOGICAL-b532t-99bde8ba8748e2631c3b08f8927c2c419bbd76388a77bd09aac7cd20d52e661a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766714/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766714/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,309,310,314,723,776,780,785,786,881,23909,23910,25118,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14363198$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12379612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Furst, D E</creatorcontrib><creatorcontrib>Breedveld, F C</creatorcontrib><creatorcontrib>Kalden, J R</creatorcontrib><creatorcontrib>Smolen, J S</creatorcontrib><creatorcontrib>Antoni, C E</creatorcontrib><creatorcontrib>Bijlsma, J W J</creatorcontrib><creatorcontrib>Burmester, G R</creatorcontrib><creatorcontrib>Cronstein, B</creatorcontrib><creatorcontrib>Keystone, E C</creatorcontrib><creatorcontrib>Kavanaugh, A</creatorcontrib><creatorcontrib>Klareskog, L</creatorcontrib><title>Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><subject>aCL</subject><subject>ACR</subject><subject>American College of Rheumatology</subject><subject>ANA</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>anticardiolipin antibody</subject><subject>antinuclear antibody</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - therapy</subject><subject>biological agents</subject><subject>Biological and medical sciences</subject><subject>blocking agents</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Consensus Statement</subject><subject>DAS</subject><subject>disease activity score</subject><subject>disease modifying antirheumatic drug</subject><subject>DMARD</subject><subject>Drug dosages</subject><subject>HAQ-DI</subject><subject>Health Assessment Questionnaire disease index</subject><subject>Humans</subject><subject>interleukin</subject><subject>Interleukin-2 - antagonists & inhibitors</subject><subject>Medical sciences</subject><subject>methotrexate</subject><subject>MTX</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Rheumatic diseases</subject><subject>Rheumatic Diseases - therapy</subject><subject>Rheumatoid arthritis</subject><subject>TNF</subject><subject>TNF inhibitors</subject><subject>Toxicity</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><subject>tumour necrosis factor</subject><subject>tumour necrosis factor α</subject><subject>VAS</subject><subject>visual analogue scale</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkUGP0zAQhSMEYsvCH-CALCEQHFJsJ7WdCxJULCAWOMAibtbEdlqXJA4eB7FXfjlGLVvgxMnyzDdPb-YVxV1Gl4xV4glEuxRsifM09ZovvefXigWrhSo5FfR6saCUVmXdCHlS3ELc5S9VTN0sThivZCMYXxQ_LiYLyVliwohuxBkJplwY3JhIGEnrQx823kBPYJNrSLoQSdo6kqKDtMc6ErduHiAFbwnEtI0-eSQwWhIyGn-3vSHWowN0SB69hUvCKeWPbxc3OujR3Tm8p8XF2YuP61fl-fuXr9fPzst2VfFUNk1rnWpByVo5LipmqpaqTjVcGm5q1rStlaJSCqRsLW0AjDSWU7viTggG1WnxdK87ze3grMnWI_R6in6AeKkDeP13Z_RbvQnfNJNCSFZngYcHgRi-zg6THjwa1_cwujCjlpzJulnJDN7_B9yFOY55uawlpaprUdNM8T1lYkCMrruywqj-FbDOAWvB9CFgnQPOQ_f-XOI4ckg0Aw8OAGBOrYswGo9Hrq7y6RqVuXLPeUzu-1Uf4hctZCVX-t2ntf785kyunn-gWhz5dtj9j9Gf0bfS-w</recordid><startdate>20021101</startdate><enddate>20021101</enddate><creator>Furst, D E</creator><creator>Breedveld, F C</creator><creator>Kalden, J R</creator><creator>Smolen, J S</creator><creator>Antoni, C E</creator><creator>Bijlsma, J W J</creator><creator>Burmester, G R</creator><creator>Cronstein, B</creator><creator>Keystone, E C</creator><creator>Kavanaugh, A</creator><creator>Klareskog, L</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20021101</creationdate><title>Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)</title><author>Furst, D E ; Breedveld, F C ; Kalden, J R ; Smolen, J S ; Antoni, C E ; Bijlsma, J W J ; Burmester, G R ; Cronstein, B ; Keystone, E C ; Kavanaugh, A ; Klareskog, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b532t-99bde8ba8748e2631c3b08f8927c2c419bbd76388a77bd09aac7cd20d52e661a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>aCL</topic><topic>ACR</topic><topic>American College of Rheumatology</topic><topic>ANA</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>anticardiolipin antibody</topic><topic>antinuclear antibody</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - therapy</topic><topic>biological agents</topic><topic>Biological and medical sciences</topic><topic>blocking agents</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Consensus Statement</topic><topic>DAS</topic><topic>disease activity score</topic><topic>disease modifying antirheumatic drug</topic><topic>DMARD</topic><topic>Drug dosages</topic><topic>HAQ-DI</topic><topic>Health Assessment Questionnaire disease index</topic><topic>Humans</topic><topic>interleukin</topic><topic>Interleukin-2 - antagonists & inhibitors</topic><topic>Medical sciences</topic><topic>methotrexate</topic><topic>MTX</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Rheumatic diseases</topic><topic>Rheumatic Diseases - therapy</topic><topic>Rheumatoid arthritis</topic><topic>TNF</topic><topic>TNF inhibitors</topic><topic>Toxicity</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><topic>tumour necrosis factor</topic><topic>tumour necrosis factor α</topic><topic>VAS</topic><topic>visual analogue scale</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furst, D E</creatorcontrib><creatorcontrib>Breedveld, F C</creatorcontrib><creatorcontrib>Kalden, J R</creatorcontrib><creatorcontrib>Smolen, J S</creatorcontrib><creatorcontrib>Antoni, C E</creatorcontrib><creatorcontrib>Bijlsma, J W J</creatorcontrib><creatorcontrib>Burmester, G R</creatorcontrib><creatorcontrib>Cronstein, B</creatorcontrib><creatorcontrib>Keystone, E C</creatorcontrib><creatorcontrib>Kavanaugh, A</creatorcontrib><creatorcontrib>Klareskog, L</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furst, D E</au><au>Breedveld, F C</au><au>Kalden, J R</au><au>Smolen, J S</au><au>Antoni, C E</au><au>Bijlsma, J W J</au><au>Burmester, G R</au><au>Cronstein, B</au><au>Keystone, E C</au><au>Kavanaugh, A</au><au>Klareskog, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2002-11-01</date><risdate>2002</risdate><volume>61</volume><issue>suppl 2</issue><spage>ii2</spage><epage>ii7</epage><pages>ii2-ii7</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>12379612</pmid><doi>10.1136/ard.61.suppl_2.ii2</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2002-11, Vol.61 (suppl 2), p.ii2-ii7 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1766714 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | aCL ACR American College of Rheumatology ANA Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use anticardiolipin antibody antinuclear antibody Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - therapy biological agents Biological and medical sciences blocking agents Bones, joints and connective tissue. Antiinflammatory agents Consensus Statement DAS disease activity score disease modifying antirheumatic drug DMARD Drug dosages HAQ-DI Health Assessment Questionnaire disease index Humans interleukin Interleukin-2 - antagonists & inhibitors Medical sciences methotrexate MTX Patients Pharmacology. Drug treatments Rheumatic diseases Rheumatic Diseases - therapy Rheumatoid arthritis TNF TNF inhibitors Toxicity Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF tumour necrosis factor tumour necrosis factor α VAS visual analogue scale |
| title | Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T08%3A07%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Updated%20consensus%20statement%20on%20biological%20agents%20for%20the%20treatment%20of%20rheumatoid%20arthritis%20and%20other%20rheumatic%20diseases%20(May%202002)&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Furst,%20D%20E&rft.date=2002-11-01&rft.volume=61&rft.issue=suppl%202&rft.spage=ii2&rft.epage=ii7&rft.pages=ii2-ii7&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.61.suppl_2.ii2&rft_dat=%3Cproquest_pubme%3E4008347651%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777844640&rft_id=info:pmid/12379612&rfr_iscdi=true |